Rekha Hans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rekha Hans has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Ratti Ram Sharma
Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
7 shared publications Neelam Marwaha
Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
5 shared publicationsRatti Ram Sharma
Department of Transfusion Medicine Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh India
5 shared publications- Divjot Singh Lamba
Department of Transfusion Medicine Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh India
3 shared publications - Divjot Singh Lamba
Post Grad Inst Med Educ & Res PGIMER, Dept Transfus Med, Chandigarh, India
3 shared publications - Ajay Duseja
Department of Hepatology, PGIMER, Chandigarh, India
2 shared publications
Latest Publications
- 24 February 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (1)
Comparative Efficacy of Standard‐Volume Plasma Exchange Versus High‐Volume Plasma Exchange in Patients With Acute‐on‐Chronic Liver Failure
High‐volume therapeutic plasma exchange (HV‐TPE) is an established treatment modality in acute liver failure; however, its role in acute‐on‐chronic liver failure (ACLF) and its comparative efficacy versus standard‐volume TPE (SV‐TPE) remain unclear. This single‐center, prospective, randomized pilot study conducted over 2 years (2021–2023) compared the efficacy of HV‐TPE and SV‐TPE in patients with ACLF. Twenty‐two consecutive patients with ACLF Grade I and II without prospects for liver transplantation were enrolled; 11 patients underwent HV‐TPE, and 11 underwent SV‐TPE. In addition to tolerability, the effects of both TPE modalities on coagulation parameters, biochemical indices, cytokine levels (IL‐6, IL‐10, and TNF‐α), and clinical severity scores—including the Asia Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) score, Maddrey discriminant function (MDF), Model for End‐Stage Liver Disease (MELD), and Child‐Turcotte‐Pugh (CTP) score—were assessed before and after therapy. Length of hospital stay and 30‐day and 90‐day mortality were also compared. Both HV‐TPE and SV‐TPE resulted in significant improvement in coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR), along with significant reductions in serum total and conjugated bilirubin, alkaline phosphatase, total protein, and serum ammonia ( p < 0.05). Significant improvement in serum urea ( p = 0.004), serum creatinine ( p = 0.004), and serum lactate ( p = 0.007) was observed only in the HV‐TPE group. Clinical severity scores (AARC, MDF, MELD, and CTP) improved significantly in both groups ( p < 0.05). There were no significant differences between the groups in 30‐day mortality (27% vs. 27%, p = 1.00), 90‐day mortality (36% vs. 45%, p = 0.40), or changes in cytokine levels. Procedure‐related adverse events were infrequent and comparable between HV‐TPE (6.8%) and SV‐TPE (5.7%). In conclusion, both HV‐TPE and SV‐TPE effectively improved clinical severity scores in patients with ACLF; however, a definitive difference in mortality benefit could not be demonstrated in this study. Trial Registration: CTRI/2019/06/019660 (dated 14 June 2019)
- 24 February 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (1)
Comparative Efficacy of Standard‐Volume Plasma Exchange Versus High‐Volume Plasma Exchange in Patients With Acute‐on‐Chronic Liver Failure
High‐volume therapeutic plasma exchange (HV‐TPE) is an established treatment modality in acute liver failure; however, its role in acute‐on‐chronic liver failure (ACLF) and its comparative efficacy versus standard‐volume TPE (SV‐TPE) remain unclear. This single‐center, prospective, randomized pilot study conducted over 2 years (2021–2023) compared the efficacy of HV‐TPE and SV‐TPE in patients with ACLF. Twenty‐two consecutive patients with ACLF Grade I and II without prospects for liver transplantation were enrolled; 11 patients underwent HV‐TPE, and 11 underwent SV‐TPE. In addition to tolerability, the effects of both TPE modalities on coagulation parameters, biochemical indices, cytokine levels (IL‐6, IL‐10, and TNF‐α), and clinical severity scores—including the Asia Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) score, Maddrey discriminant function (MDF), Model for End‐Stage Liver Disease (MELD), and Child‐Turcotte‐Pugh (CTP) score—were assessed before and after therapy. Length of hospital stay and 30‐day and 90‐day mortality were also compared. Both HV‐TPE and SV‐TPE resulted in significant improvement in coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR), along with significant reductions in serum total and conjugated bilirubin, alkaline phosphatase, total protein, and serum ammonia ( p < 0.05). Significant improvement in serum urea ( p = 0.004), serum creatinine ( p = 0.004), and serum lactate ( p = 0.007) was observed only in the HV‐TPE group. Clinical severity scores (AARC, MDF, MELD, and CTP) improved significantly in both groups ( p < 0.05). There were no significant differences between the groups in 30‐day mortality (27% vs. 27%, p = 1.00), 90‐day mortality (36% vs. 45%, p = 0.40), or changes in cytokine levels. Procedure‐related adverse events were infrequent and comparable between HV‐TPE (6.8%) and SV‐TPE (5.7%). In conclusion, both HV‐TPE and SV‐TPE effectively improved clinical severity scores in patients with ACLF; however, a definitive difference in mortality benefit could not be demonstrated in this study. Trial Registration: CTRI/2019/06/019660 (dated 14 June 2019)
- 20 May 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 102594
Plasma Exchange With Corticosteroids as a Rescue Therapy for Severe Prolonged Cholestasis in Acute Viral Hepatitis
- 20 May 2025
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 15 (6) , 102594
Plasma Exchange With Corticosteroids as a Rescue Therapy for Severe Prolonged Cholestasis in Acute Viral Hepatitis
- 20 November 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (1) , 104039
Comparison of different concentrations of calcium gluconate added in replacement fluid to maintain ionised calcium levels during therapeutic plasma exchange procedures
- 20 November 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (1) , 104039
Comparison of different concentrations of calcium gluconate added in replacement fluid to maintain ionised calcium levels during therapeutic plasma exchange procedures
- 8 June 2024
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 39 (3) , e22129
Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add‐on therapy in acute attacks of neuromyelitis optica spectrum disorder
Introduction: Plasma exchange (PE) is considered a Category II option for the treatment of acute attacks and relapse cases of neuromyelitis optica spectrum disorder (NMOSD). However, neurologists are also considering intravenous immunoglobulins (IVIg) as an add‐on therapy for this disorder.Aims: The aim of this study is to evaluate the efficacy of PE in acute attacks of NMOSD when compared with IVIg, in terms of improvement in the Expanded disability status scale (EDSS) and activities of daily living (ADL) scale score and levels of anti‐Aquaporin P4 (AQP4) antibody in seropositive patients.Methods: We enrolled 43 NMOSD patients in two groups: Group 1 (n = 29) received steroids and PE, and Group 2 (n = 14) received steroids with IVIg. The baseline EDSS and ADL scores were recorded and compared with scores at the end of therapy, 4 weeks, and 3 months after. Also, anti‐AQP4 antibody was measured at baseline and post‐therapy in seropositive patients of both groups.Results: We observed a significant difference in EDSS (p = 0.00) and ADL score (p = 0.00) at day 10 and 3 months in both groups. However, no significant difference in EDSS, as well as ADL score from baseline (p = 0.83; p = 0.25) to 3 months (p = 0.85; p = 0.19), was observed when delta change of score at 3 months was compared across the two groups (p = 0.39; p = 0.52). We observed improved visual acuity in both groups with mild improvement in findings of magnetic resonance imaging at 3 months. We observed a significant decline in AQP4 antibody concentration (at day 10) in group 1 seropositive patients (p = 0.013) with improved EDSS (p = 0.027) and ADL scores (p = 0.026) of these patients.Conclusions: PE should be considered as a choice of an add‐on therapy in anti‐AQP4 antibody‐positive NMOSD patients compared with IVIg as it is more effective in reducing antibody concentrations.
- 8 June 2024
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 39 (3) , e22129
Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add‐on therapy in acute attacks of neuromyelitis optica spectrum disorder
Introduction: Plasma exchange (PE) is considered a Category II option for the treatment of acute attacks and relapse cases of neuromyelitis optica spectrum disorder (NMOSD). However, neurologists are also considering intravenous immunoglobulins (IVIg) as an add‐on therapy for this disorder.Aims: The aim of this study is to evaluate the efficacy of PE in acute attacks of NMOSD when compared with IVIg, in terms of improvement in the Expanded disability status scale (EDSS) and activities of daily living (ADL) scale score and levels of anti‐Aquaporin P4 (AQP4) antibody in seropositive patients.Methods: We enrolled 43 NMOSD patients in two groups: Group 1 (n = 29) received steroids and PE, and Group 2 (n = 14) received steroids with IVIg. The baseline EDSS and ADL scores were recorded and compared with scores at the end of therapy, 4 weeks, and 3 months after. Also, anti‐AQP4 antibody was measured at baseline and post‐therapy in seropositive patients of both groups.Results: We observed a significant difference in EDSS (p = 0.00) and ADL score (p = 0.00) at day 10 and 3 months in both groups. However, no significant difference in EDSS, as well as ADL score from baseline (p = 0.83; p = 0.25) to 3 months (p = 0.85; p = 0.19), was observed when delta change of score at 3 months was compared across the two groups (p = 0.39; p = 0.52). We observed improved visual acuity in both groups with mild improvement in findings of magnetic resonance imaging at 3 months. We observed a significant decline in AQP4 antibody concentration (at day 10) in group 1 seropositive patients (p = 0.013) with improved EDSS (p = 0.027) and ADL scores (p = 0.026) of these patients.Conclusions: PE should be considered as a choice of an add‐on therapy in anti‐AQP4 antibody‐positive NMOSD patients compared with IVIg as it is more effective in reducing antibody concentrations.
- 6 September 2022
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 37 (6) , 553-562
Therapeutic plasma exchange is a safe and effective bridge therapy in patients with alcohol‐associated ACLF not having immediate prospects for liver transplantation—A case‐control, pilot study
Background: Therapeutic plasma exchange (TPE) is a well‐established treatment modality in acute liver failure patients, but its efficacy in treating acute on chronic liver failure (ACLF) patients is yet to be established.Aim: To assess the efficacy and safety of TPE in patients with alcohol‐associated ACLF who were nonresponders to standard medical treatment (SMT) and without immediate prospects for liver transplantation.Methods: Twenty‐eight alcohol‐related ACLF (grade II) patients (14 cases and 14 controls) were enrolled in the study. Cases underwent standard volume TPE along with SMT while the controls were on SMT alone. The change (baseline to day 10) in laboratory parameters, cytokine concentrations, clinical severity scores along with 30 and 90 day mortality rates were noted and compared between the two groups. The adverse events (AEs) were noted in the groups and analyzed.Results: A total of 51 TPE procedures were performed in 14 patients (average of 3.62 procedures/patient). TPE was effective in reduction of serum bilirubin, ammonia, activated partial thromboplastin time, prothrombin time, international normalized ratio, and severity scores (ACLF Research Consortium, Maddrey's discriminant function, and model for end‐stage liver disease) (P < .05). There was no significant difference in the reduction of serum interleukin‐6 (IL‐6), IL‐10, and tumor necrosis factor‐α concentrations among cases. Among the cases who received the complete TPE interventions, 30‐ and 90‐day mortality rates were lower in the cases as compared to controls albeit only the 90‐day mortality was significantly different. Procedure‐related AEs was observed in 2% of procedures.Conclusion: TPE is an effective and well‐tolerated bridge therapy in patients with alcohol‐associated ACLF of moderate severity not improving on SMT and without immediate prospects for liver transplantation.
- 6 September 2022
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 37 (6) , 553-562
Therapeutic plasma exchange is a safe and effective bridge therapy in patients with alcohol‐associated ACLF not having immediate prospects for liver transplantation—A case‐control, pilot study
Background: Therapeutic plasma exchange (TPE) is a well‐established treatment modality in acute liver failure patients, but its efficacy in treating acute on chronic liver failure (ACLF) patients is yet to be established.Aim: To assess the efficacy and safety of TPE in patients with alcohol‐associated ACLF who were nonresponders to standard medical treatment (SMT) and without immediate prospects for liver transplantation.Methods: Twenty‐eight alcohol‐related ACLF (grade II) patients (14 cases and 14 controls) were enrolled in the study. Cases underwent standard volume TPE along with SMT while the controls were on SMT alone. The change (baseline to day 10) in laboratory parameters, cytokine concentrations, clinical severity scores along with 30 and 90 day mortality rates were noted and compared between the two groups. The adverse events (AEs) were noted in the groups and analyzed.Results: A total of 51 TPE procedures were performed in 14 patients (average of 3.62 procedures/patient). TPE was effective in reduction of serum bilirubin, ammonia, activated partial thromboplastin time, prothrombin time, international normalized ratio, and severity scores (ACLF Research Consortium, Maddrey's discriminant function, and model for end‐stage liver disease) (P < .05). There was no significant difference in the reduction of serum interleukin‐6 (IL‐6), IL‐10, and tumor necrosis factor‐α concentrations among cases. Among the cases who received the complete TPE interventions, 30‐ and 90‐day mortality rates were lower in the cases as compared to controls albeit only the 90‐day mortality was significantly different. Procedure‐related AEs was observed in 2% of procedures.Conclusion: TPE is an effective and well‐tolerated bridge therapy in patients with alcohol‐associated ACLF of moderate severity not improving on SMT and without immediate prospects for liver transplantation.
- Open Access
- 7 July 2021
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 25 (7) , 828-829
Therapeutic Plasma Exchange: A Lifesaving Therapy in Case of ANCA-associated Vasculitis with Diffuse Alveolar Hemorrhage
How to cite this article: Tripathi PP, Sharma RR, Chhabria B, Hans R, Sehgal IS. Therapeutic Plasma Exchange: A Lifesaving Therapy in Case of ANCA-associated Vasculitis with Diffuse Alveolar Hemorrhage. Indian J Crit Care Med 2021;25(7):828–829.
- 7 July 2021
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 25 (7) , 828-829
Open AccessTherapeutic Plasma Exchange: A Lifesaving Therapy in Case of ANCA-associated Vasculitis with Diffuse Alveolar Hemorrhage
How to cite this article: Tripathi PP, Sharma RR, Chhabria B, Hans R, Sehgal IS. Therapeutic Plasma Exchange: A Lifesaving Therapy in Case of ANCA-associated Vasculitis with Diffuse Alveolar Hemorrhage. Indian J Crit Care Med 2021;25(7):828–829.
- 20 May 2021
- Published by Wiley in Vox Sanguinis
- Vol. 116 (10) , E71-E120
International Forum on the Collection and Use of COVID‐19 Convalescent Plasma: Responses
- 20 May 2021
- Published by Wiley in Vox Sanguinis
- Vol. 116 (10) , E71-E120
International Forum on the Collection and Use of COVID‐19 Convalescent Plasma: Responses
- 1 August 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (4) , 102809
Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A) – A case report
- 1 August 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (4) , 102809
Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A) – A case report
- Open Access
- 1 February 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (1) , 102610
Comparison of efficacy of low and high dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients
- 1 February 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (1) , 102610
Open AccessComparison of efficacy of low and high dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients
- 13 May 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (5) , e36-e90
Vox Sanguinis International Forum on paediatric indications for blood component transfusion
- 13 May 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (5) , e36-e90
Vox Sanguinis International Forum on paediatric indications for blood component transfusion